MedTrace Logo

Implementation of Precision Medicine in High-risk Prostate Cancer

NCT06687421 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5500

Last updated 2025-09-03

No results posted yet for this study

Summary

This project's objective is to initiate a prospective non-interventional clinical study to perform full molecular characterization and subtyping of the primary tumor prostate cancer patients.

It will identify, compare, and select biomarkers for treatment response in high-risk/metastatic prostate cancer.

Conditions

Interventions

OTHER

High-risk treatment SOC

radiotherapy (RT) + ADT (3 years) + Abiraterone acetate (2 years), with radical prostatectomy being an option if contraindication for RT exists)

OTHER

Active monitoring

Followed with PSA measurements

PROCEDURE

Radical prostatectomy

Radical prostatectomy

RADIATION

Radiotherapy

Radiotherapy

DRUG

Androgen deprivation therapy

GnRH agonist + abiraterone acetate/enzalutamide and/or docetaxel

Sponsors & Collaborators

  • Umeå University

    collaborator OTHER

  • Andreas Josefsson

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-10
Primary Completion
2054-12-31
Completion
2054-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06687421 on ClinicalTrials.gov